NeoGenomics (NASDAQ:NEO) Stock Rating Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded NeoGenomics from “Buy” to “Hold,” although broader analyst sentiment remains “Moderate Buy,” with eight Buy, three Hold, and one Sell rating and a consensus price target of $20.88.
• NeoGenomics reported quarterly earnings of $0.07 per share, beating estimates by $0.01, while revenue rose 11.3% year over year to $209.25 million. However, the company posted a negative net margin and analysts expect a full-year loss.
• Shares opened at $17.38, up significantly from the 52-week low of $7.07 but below the $20.15 high; institutional investors and hedge funds own approximately 98.5% of the stock.

NeoGenomics (NASDAQ:NEO - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC increased their price objective on shares of NeoGenomics from $19.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, October 6th. Benchmark boosted their target price on NeoGenomics from $11.00 to $16.00 and gave the stock a "buy" rating in a report on Friday, July 24th. Weiss Ratings restated a "sell (d-)" rating on shares of NeoGenomics in a research report on Monday, October 12th. Jefferies Financial Group restated a "buy" rating and issued a $21.00 target price on shares of NeoGenomics in a research report on Thursday. Finally, TD Cowen increased their price target on NeoGenomics from $19.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $20.88.

NeoGenomics Stock Performance

Shares of NEO opened at $17.38 on Friday. The firm has a 50-day moving average price of $17.68 and a 200 day moving average price of $12.82. The company has a current ratio of 3.53, a quick ratio of 3.35 and a debt-to-equity ratio of 0.47. NeoGenomics has a 52-week low of $7.07 and a 52-week high of $20.15.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Wednesday, October 28th. The medical research company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The firm had revenue of $209.25 million for the quarter, compared to analysts' expectations of $206.70 million. During the same quarter last year, the company earned $0.03 EPS. NeoGenomics's quarterly revenue was up 11.3% on a year-over-year basis. On average, sell-side analysts predict that NeoGenomics will post -0.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeoGenomics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Root Financial Partners LLC acquired a new stake in shares of NeoGenomics during the 3rd quarter valued at $29,000. GAMMA Investing LLC boosted its stake in shares of NeoGenomics by 30.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,782 shares of the medical research company's stock worth $51,000 after acquiring an additional 644 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of NeoGenomics by 117.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,701 shares of the medical research company's stock worth $31,000 after acquiring an additional 917 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of NeoGenomics by 26.2% during the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company's stock worth $179,158,000 after acquiring an additional 2,549,545 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in shares of NeoGenomics in the 2nd quarter worth $925,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q3 results exceeded expectations. NeoGenomics reported third-quarter revenue of approximately $209 million, up 11.3% year over year, while earnings per share of $0.07 topped the $0.06 consensus estimate. NeoGenomics third-quarter earnings results
• Positive Sentiment: Management raised its full-year outlook. The company increased 2026 revenue guidance to $807 million-$809 million, signaling continued demand for its cancer-testing and laboratory-services business. The improved outlook was highlighted alongside the earnings beat. NeoGenomics raises 2026 guidance
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial upside from recent trading levels. Investors also continue to assess whether the earnings beat and higher guidance leave the stock attractively valued. BTIG Research rating
• Neutral Sentiment: CEO transition planned for January 2027. NeoGenomics disclosed that its chief executive transition is expected early next year. The change could eventually support new strategic initiatives, but investors may initially seek more clarity on succession and execution. NeoGenomics 2026 third-quarter earnings presentation
• Negative Sentiment: Profitability remains a concern. Although adjusted quarterly earnings beat estimates, the company continues to face pressure from weak reported profitability, with a negative net margin and analysts expecting a full-year loss. This may be limiting the stock’s reaction to the stronger revenue outlook.

NeoGenomics Company Profile

NeoGenomics, Inc NASDAQ: NEO is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company's services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.